Why Carlisle Companies Incorporated (CSL) stock moved
Carlisle Companies Incorporated (CSL) shares rose 3.9% to $326.37 as of September 26, 2026, a moderate gain from the prior close of $314.13. BestStocks flagged the session as a major change for CSL. Below, we break down what changed for CSL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CSL climbed 3.9% to $326.37
CSL rose 3.9% in its latest session, moving from $314.13 to $326.37.
What it means for Carlisle Companies Incorporated investors
For Carlisle Companies Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 3.9% session move. Weighing against that: Carlisle Companies Incorporated moved -3.03% intraday from $323.96 to $314.13; CSL stock fell 2.15% to $339.13, driven by pressure from the Trump administration targeting pharmaceutical companies to cut US drug prices, per web sources. Wall Street's consensus price target sits at $406.40, implying +24.5% upside from $326.37. BestStocks rates the overall signal quality low (54/100). With earnings roughly 39 days out, the next report is the most likely near-term test of the move.
CSL price reaction
CSL last traded at $326.37, up $12.24 (+3.90%) from the previous close of $314.13. The session traded on 1.1× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $314.13 and $365.72, and it currently sits about 24% of the way up that band.
Bullish and bearish analyst opinions on Carlisle Companies Incorporated (CSL)
The consensus analyst price target on Carlisle Companies Incorporated (CSL) is $406.40, 24.5% above the recent $326.37. Over the past 90 days analysts logged 0 upgrades, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CSL line up.
The bullish case
- Wall Street's consensus price target of $406.40 implies +24.5% upside from $326.37.
- The Street's most bullish target is $425.00 (+30.2%).
- Material positive event.
- Positive 3.9% session move.
- Positive price momentum.
The bearish case
- Carlisle Companies Incorporated moved -3.03% intraday from $323.96 to $314.13.
- CSL stock fell 2.15% to $339.13, driven by pressure from the Trump administration targeting pharmaceutical companies to cut US drug prices, per web sources.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 25, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CSL
Frequently asked questions about CSL
Why did Carlisle Companies Incorporated (CSL) stock move?
CSL rose 3.9% to $326.37. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did CSL stock rise?
CSL gained 3.90% ($12.24) versus the prior close of $314.13, last trading at $326.37 on 1.1× average volume.
When is Carlisle Companies Incorporated's next earnings date?
CSL's next earnings report is estimated for 2026-11-04 — about 39 days away.
What is the analyst price target for CSL?
The consensus analyst price target for CSL is $406.40, about 24.5% above the current $326.37. Over the past 90 days, analysts recorded 0 upgrades, 2 maintains, and 0 downgrades.
How BestStocks tracks CSL
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CSL-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for CSL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 26, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.